טוען...
Rheumatic complications in cancer patients treated with immune checkpoint inhibitors
Immune checkpoint inhibitors (ICIs) have revolutionized anticancer therapy due to their long-term clinical benefits and immune boosting mechanisms. However, despite their consistent therapeutic effects, the use of ICIs is associated with a spectrum of adverse events due to their autoimmune and auto-...
שמור ב:
| הוצא לאור ב: | Korean J Intern Med |
|---|---|
| Main Authors: | , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
The Korean Association of Internal Medicine
2019
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6823575/ https://ncbi.nlm.nih.gov/pubmed/31014065 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3904/kjim.2019.060 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|